tiprankstipranks
Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
UK Market
POLB
Poolbeg Pharma Ltd.
RESEARCH TOOLSreports
Want to see GB:POLB full AI Analyst Report?

Poolbeg Pharma Ltd. (POLB) Earnings Dates, Call Summary & Reports

28 Followers

Earnings Data

Report Date
Sep 08, 2026
TBA (Not Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
―
Last Year’s EPS
>-0.01
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Apr 28, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed strong progress across regulatory, IP, preclinical/clinical readiness and partnership engagement, supported by concrete metrics (GBP 7.7m cash, GBP 4.865m fundraising, GBP 3.4m grant, Orphan Drug designation, patents, ~85%–95% cytokine inhibition in LPS model). Key upcoming inflection points (TOPICAL interim readout expected summer 2026; oral GLP-1 trial in H2 2026) underpin near-term value catalysts. Offset risks include a manufacturing delay for the GLP-1 program, a small open-label TOPICAL study requiring further confirmatory work, dependence on partners for late-stage development/commercialization, and a funding runway limited to 2027. On balance, highlights materially outweigh lowlights given the substantive regulatory milestones, strong early efficacy signals, payer interest and active partnering — suggesting positive momentum ahead of the summer data readout.
Company Guidance
Management guided that Poolbeg has financial runway into 2027 (cash £7.7m at FY2025, following a £4.865m fundraising and with a £3.4m RISE grant), that the POLB‑001 TOPICAL CRS‑prevention trial is fully prepared (MHRA approval, ACT as CRO, J&J supplying teclistamab at no cost) and will enroll ~30 relapsed/refractory multiple myeloma patients across 6 U.K. sites with twice‑daily dosing around the 5–8 day step‑up teclistamab period (when ~96–100% of CRS occurs), with interim data expected in summer 2026; this builds on a Phase Ib LPS human challenge (30/70/150 mg BID) showing dose‑response and ~85–95% suppression of IL‑6/IL‑8 (p38 inhibition ~80–90%). They reiterated a >$10bn U.S./EU5 market opportunity (modeled from ~500,000 patients 2023–2030 and an illustrative ~$20,000 price point vs Neulasta’s ~$18,000), noted >70% CRS incidence with some T‑cell engagers, Grade‑3 CRS management costs >$70,000, patent coverage to at least 2044, and that an oral GLP‑1 PK/safety study in 20 volunteers is planned for H2 2026.
Clinical Progress — TOPICAL (POLB 001) Ready to Start
MHRA approval obtained, protocol finalized, 6 UK sites secured (The Christie, UCH, Royal Marsden, Birmingham, NHS North Midlands/Royal Stoke, Edinburgh), ACT appointed as CRO, J&J supplying teclistamab at no cost, patient recruitment and dosing imminent for ~30 relapsed/refractory multiple myeloma patients.
Strong Efficacy Signal from LPS Human Challenge
Placebo-controlled LPS challenge in healthy volunteers showed dose-dependent suppression of key cytokines (IL-6, IL-8). The two upper POLB 001 doses achieved approximately 85%–95% inhibition of cytokine induction, demonstrating potent target engagement without immunosuppression.
Regulatory and IP Achievements
U.S. FDA Orphan Drug designation received for POLB 001 related indication; multiple patents granted (including Australia) and broad patent family projected to give coverage to at least 2044.
Financial Position and Fundraising
Cash balance of GBP 7.7 million at year-end with financial runway into 2027. Successfully raised GBP 4.865 million in 2025 despite challenging market conditions.
Significant Market Opportunity Identified
Independent analysis estimates >USD 10 billion peak market opportunity for CRS prevention in bispecifics and CAR T in the U.S. and EU5. Analysis based on ~500,000 eligible patients (2023–2030) and a pricing comparator in the ~USD 18–20k per treatment range.
Partnership and Payer Interest
Active partnering discussions with multiple large and midsize pharma; virtual data room open. Feedback from three U.S. payers covering ~75 million lives indicates willingness to pay for a CRS preventative that reduces hospitalization and overall costs.
Academic and Grant Support
GBP 3.4 million RISE grant awarded to University of Manchester and The Christie (Poolbeg is lead business partner) to fund broader CRS research, combining industry (J&J), academic and clinical resources.
Additional Program — Oral GLP-1 Development
Oral GLP-1 program progressing with clinical trial design ready; partnered with AnaBio for encapsulation technology; planned Phase I study of ~20 volunteers to assess safety, tolerability and PK in H2 2026 (start delayed due to manufacturing lead times).

Poolbeg Pharma Ltd. (GB:POLB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

GB:POLB Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Sep 08, 2026
2026 (Q2)
- / -
-0.004―――
Apr 28, 2026
2025 (Q4)
- / >-0.01
-0.00728.57% (<+0.01)――
Sep 29, 2025
2025 (Q2)
>-0.01 / >-0.01
-0.0040.00% (0.00)――
May 20, 2025
2024 (Q4)
- / >-0.01
-0.004-75.00% (>-0.01)――
Sep 18, 2024
2024 (Q2)
>-0.01 / >-0.01
-0.0040.00% (0.00)――
Apr 30, 2024
2023 (Q4)
- / >-0.01
-0.00633.33% (<+0.01)――
Sep 13, 2023
2023 (Q2)
- / >-0.01
-0.003-33.33% (>-0.01)――
Mar 30, 2023
2022 (Q4)
- / >-0.01
――――
Sep 06, 2022
2022 (Q2)
>-0.01 / >-0.01
――――
Mar 03, 2022
2021 (Q4)
- / -
――――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:POLB Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 28, 2026
4.45 p4.30 p-3.37%
Sep 29, 2025
3.90 p4.00 p+2.56%
May 20, 2025
2.85 p2.60 p-8.77%
Sep 18, 2024
9.80 p10.10 p+3.06%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Poolbeg Pharma Ltd. (GB:POLB) report earnings?
Poolbeg Pharma Ltd. (GB:POLB) is schdueled to report earning on Sep 08, 2026, TBA (Not Confirmed).
    What is Poolbeg Pharma Ltd. (GB:POLB) earnings time?
    Poolbeg Pharma Ltd. (GB:POLB) earnings time is at Sep 08, 2026, TBA (Not Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Poolbeg Pharma Ltd. stock?
          The P/E ratio of Poolbeg Pharma Ltd. is N/A.
            What is GB:POLB EPS forecast?
            Currently, no data Available